Galapagos NV, a biotechnology company listed on Euronext and NASDAQ, announced the creation of a new subscription right plan aimed at compensating its senior management. On August 7, 2025, the company's Board of Directors approved "Subscription Right Plan 2025 $(B)$," which involves the creation of 1,800,000 subscription rights. These rights, subject to acceptance, allow senior management to subscribe to new Galapagos shares at an exercise price of €28.16 per share. The rights have an eight-year exercise term but cannot be exercised until the third anniversary of issuance. This plan is intended to align the interests of senior management with those of the shareholders by offering them a stake in the company's growth.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。